Previous Page  20 / 20
Information
Show Menu
Previous Page 20 / 20
Page Background

Page 81

Notes:

Journal of Glycobiology | ISSN: 2168-958X | Volume 7

Glycobiology & Glycoproteomics

5

th

International Conference on

&

August 27-28, 2018 | Toronto, Canada

Molecular Biology & Nucleic Acids

3

rd

International Conference on

The structural basis for the interdependence of drug resistance: HIV-1 protease

Debra Ragland

University of Massachusetts Medical School, USA

H

IV-1 protease is responsible for the cleavage of 12 non-homologous sites within the Gag and Gag-Pro-Pol polyproteins in the

viral genome. Under the selective pressure of protease inhibition, the virus evolves mutations within (primary) and outside

of (secondary) the active site, allowing the protease to process substrates while simultaneously countering inhibition. The primary

protease mutations impede inhibitor binding directly, while the secondary mutations are considered accessory mutations that

compensate for a loss in fitness. However, the role of secondary mutations in conferring drug resistance remains a largely unresolved

topic. We have shown previously that mutations distal to the active site are able to perturb binding of darunavir (DRV) via the

protein's internal hydrogen-bonding network. In this study, we show that mutations distal to the active site, regardless of context,

can play an interdependent role in drug resistance. Applying eigenvalue decomposition to collections of hydrogen bonding and van

der Waals interactions from a series of molecular dynamics simulations of 15 diverse HIV-1 protease variants, we identify sites in the

protease where amino acid substitutions lead to perturbations in nonbonded interactions with DRV and/or the hydrogen-bonding

network of the protease itself. While primary mutations are known to drive resistance in HIV-1 protease, these findings delineate the

significant contributions of accessory mutations to resistance. Identifying the variable positions in the protease that have the greatest

impact on drug resistance may aid in the future structure-based design of inhibitors.

draglan@clemson.edu

J Glycobiol 2018, Volume 7

DOI: 10.4172/2168-958X-C1-012